XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation and Significant Accounting Policies - Stock-Based Compensation (Details)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
May 31, 2022
shares
Sep. 30, 2022
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
Jun. 30, 2022
$ / shares
shares
Sep. 30, 2022
USD ($)
plan
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
shares
Jun. 15, 2022
shares
Apr. 01, 2022
shares
Jun. 30, 2018
shares
Stock-Based Compensation                      
Number of employee share-based compensation plans | plan         3            
Weighted-average assumptions used to estimate the fair value of each stock option                      
Dividend (as a percent)   0.00% 0.00%   0.00% 0.00%          
ESPP                      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]                      
Aggregate number of common shares reserved for future issuance                     2,000,000
Stock options and restricted stock awards                      
Stock-Based Compensation                      
Vesting period         3 years            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]                      
Stock compensation expense | $   $ 5.3 $ 3.3   $ 14.3 $ 10.6          
Estimated fair value that could be expensed | $   $ 54.3     $ 54.3            
Stock options                      
Weighted-average assumptions used to estimate the fair value of each stock option                      
Dividend (as a percent)   0.00% 0.00%   0.00% 0.00%          
Volatility (as a percent)   83.30% 82.70%   83.20% 85.20%          
Risk-free interest rate (as a percent)   3.44% 0.95%   2.48% 0.68%          
Expected life   5 years 7 months 6 days 6 years   5 years 10 months 24 days 6 years          
Weighted-average grant date fair value (in dollars per share) | $ / shares   $ 3.62 $ 3.99   $ 3.58 $ 5.34          
Number of Stock Options                      
Outstanding at the beginning of the period (in shares)       21,219,000 21,219,000            
Granted (in shares)         11,290,000            
Exercised (in shares)         (280,000)            
Forfeited/Canceled (in shares)       (825,000)              
Outstanding at the end of the period (in shares)   31,404,000     31,404,000   21,219,000        
Weighted-Average Exercise Price                      
Outstanding at the beginning of the period (in dollars per share) | $ / shares       $ 6.28 $ 6.28            
Granted (in dollars per share) | $ / shares         5.05            
Exercised (in dollars per share) | $ / shares         3.82            
Forfeited/Canceled (in dollars per share) | $ / shares       $ 9.46              
Outstanding at the end of the period (in dollars per share) | $ / shares   $ 5.78     $ 5.78   $ 6.28        
Performance shares                      
Stock-Based Compensation                      
Vesting percentage 25.00%                    
Number of Stock Options                      
Granted (in shares) 2,600,000             2,600,000      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]                      
Stock compensation expense | $             $ 2.6        
Estimated fair value that could be expensed | $   $ 7.8     $ 7.8            
Restricted stock                      
Number of Restricted Stock Shares                      
Unvested at the beginning of the period (in shares)       77,000 77,000            
Vested (in shares)         (2,000)            
Unvested at the end of the period (in shares)   75,000     75,000   77,000        
Weighted-Average Grant Date Fair Value                      
Unvested at the beginning of the period (in dollars per share) | $ / shares       $ 5.59 $ 5.59            
Vested (in dollars per share) | $ / shares         2.53            
Unvested at the end of the period (in dollars per share) | $ / shares   $ 5.68     $ 5.68   $ 5.59        
Immunogen Inc Restated Stock Option Plan                      
Stock-Based Compensation                      
Common stock authorized for issuance (in shares)                   28,742,013  
2018 Plan                      
Stock-Based Compensation                      
Common stock authorized for issuance (in shares)                 13,000,000    
Inducement Plan                      
Stock-Based Compensation                      
Number of employee share-based compensation plans | plan         2            
Common stock authorized for issuance (in shares)   10,500,000     10,500,000            
2018 Plan and Inducement Plan                      
Stock-Based Compensation                      
Exercise period         10 years            
2018 Plan and Inducement Plan | Maximum                      
Stock-Based Compensation                      
Vesting period         4 years